Find Academic Supervisors

Lars Engstrand is a Professor in infection control at Karolinska Institutet, heading the Translational Microbiome Research and Pandemic Preparedness group within the Department of Microbiology, Tumor and Cell Biology. His research spans multiple disciplines with a focus on translational microbiome research and pandemic preparedness. Engstrand's research interests center on understanding the human microbiome's role in health and disease, particularly in women's reproductive health and gastroenterology. His group has established multiple large-scale clinical studies including SweMaMi (Swedish Maternal Microbiome project), BASIC (associations between microbiota and preterm birth), VaMiGyn (Vaginal Microbiota in Gynaecological health), and several others investigating the vaginal microbiome's relationship to pregnancy outcomes, HPV infection, and cervical cancer. His team also conducts significant research on gut microbiome in inflammatory bowel disease and colorectal conditions through projects like PopCol and KOLBIBAKT. Analysis of Engstrand's most recent publications reveals a strong focus on the relationship between microbiome composition and women's health outcomes. His research consistently examines how vaginal, gut, and oral microbiomes influence pregnancy complications, preterm birth, HPV infection, and mental health during pregnancy. The work often employs large cohort studies with comprehensive sampling strategies across multiple body sites and time points, providing robust data for understanding microbiome dynamics in health and disease. Engstrand leads the Microbiome Exploration and Development for Intervention (MEDI) initiative and the National Pandemic Center (NPC) at Karolinska Institutet. The NPC conducted large-scale sequencing during the COVID-19 pandemic and has amassed over 1.5 million samples. His research group includes multiple specialized teams focusing on culturomics, bioinformatics, labcore operations, women's health research, and pandemic preparedness.

• Microbiome Research
• Women's Reproductive Health
• Gastroenterology
• +7 more

Professor Linda He Hong-Gu is a faculty member at the Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore. As Programme Director for Master of Science (Nursing) and Doctor of Philosophy programs, she leads graduate research initiatives and co-convenes the Women and Children Health Care Research Programme. Doctor of Philosophy, University of Eastern Finland Master of Science in Nursing, University of Eastern Finland Clinical Medicine, Fujian Medical University Her research spans Women and Children Health Care , Chronic Illness Management , and Health Technology , with over 200 peer-reviewed publications. Recent work focuses on digital interventions for improving mental health outcomes, perioperative care through technology, and preventive health behaviors in maternal populations. Publications emphasize systematic reviews , meta-analyses , and mobile health applications across diverse domains: dementia care, stroke rehabilitation, cancer support, diabetes management, and pediatric surgery preparation. Collaborations span Finland, Norway, China, and Singapore. Scientific recognition includes: Fellow of American Academy of Nursing (FAAN), 2021 International Nurse Researcher Hall of Fame, 2023 Multiple Best Poster/Oral Presentation Awards (2013-2024) Teaching Excellence Awards from NUS As an active grant recipient, she has secured over S$17.9 million in research funding from organizations like NMRC, Business Finland, and National Natural Science Foundation of China, driving innovations in AI-powered VR rehabilitation , STOMA care , and psychosocial interventions .

• Nursing Education
• Women and Children Health Care
• Chronic Illness Management
• +5 more

Angelica Lindén Hirschberg is a Professor of Obstetrics and Gynecology (specializing in reproductive medicine) at Karolinska Institutet and a Senior Consultant in gynecological endocrinology at Karolinska University Hospital. She holds dual roles in academic leadership and clinical practice, focusing on disorders of reproductive function, endocrine-metabolic dysfunction, and hormonal conditions in women. Her affiliations include the Department of Women’s and Children’s Health, Reproductive Endocrinology and Metabolism Research Group, and the Division for Neonatology, Obstetrics, Gynaecology, and Reproductive Health. Education and Career: MD (Karolinska Institutet, 1984) PhD (Karolinska Institutet, 1989) Professor in Obstetrics and Gynecology (2007) Board member of international societies (ISGE, EMAS) Research Focus: Her translational research spans PCOS, obesity-related reproductive dysfunction, premature ovarian insufficiency, and disorders of sex development. Projects include hormonal impacts on athletic performance, immune therapy for ovarian dysfunction, and endometrial cell biology. Collaborations involve national/international networks and clinical trials (e.g., PROBES trial). Publications: Recent work emphasizes PCOS pathophysiology, menopausal health, and hormonal interventions in athletes. Key trends include single-cell profiling of endometrium, immunomodulatory therapies for POI, and non-hormonal treatments for vasomotor symptoms. Awards: King’s Seraphim Medal (2018) 2016 Grand Prize in Sport Science Appointed Royal Gynecologist (2009) Teaching and Mentorship: Coordinates courses on reproductive endocrinology, supervises PhD students (e.g., Esin Ylmaz), and chairs the PhD Study Director at her department. Authored over 25 book chapters on women’s health and sports medicine. Grants and Labs: Secured Swedish Research Council funding for POI trials. Her lab integrates experimental (Bioclinicum) and clinical (Women’s Health Research Unit) research.

• Reproductive Medicine
• Endocrinology
• Polycystic Ovary Syndrome (PCOS)
• +5 more

Professor Kristina Gemzell Danielsson is a Senior Physician and Head of the Department of Women's and Children's Health at Karolinska Institutet. She holds a Docent title (2000) and has been employed at Karolinska since 2006. Her research focuses on reproductive health, obstetrics, and gynaecology, with a particular emphasis on medical abortion protocols, contraception efficacy, and global health equity. She leads initiatives to improve access to safe abortion services and has contributed to policy reforms in reproductive health care. Her academic roles include: Head of Division for Neonatology, Obstetrics, Gynaecology, and Reproductive Health Member of international advisory boards on reproductive medicine Research interests span reproductive medicine, hormonal contraception safety, and the intersection of gender-based violence with healthcare. Key contributions include studies on telemedicine abortion, epigenetic biomarkers in cancer risk, and endometriosis pathophysiology. Her publications analyze over 50 studies, emphasizing translational research and global health impact. Notable work includes randomized controlled trials on medical abortion protocols and systematic reviews on climate change and sexual health.

• Reproductive Medicine
• Obstetrics
• Gynaecology
• +3 more

Professor Caroline Ford is a leading researcher at the University of New South Wales, serving within the School of Women's and Children's Health and the Adult Cancer Program at the Lowy Cancer Research Centre. She leads the Gynaecological Cancer Research Group (GCRG), which focuses on understanding the development, spread, and treatment of gynaecological cancers, with particular emphasis on ovarian and endometrial cancer. Established in 2010 after international postdoctoral fellowships at the University of Toronto and Lund University, her laboratory has maintained consistent competitive research funding for over 13 years. Her research spans Cancer Cell Biology with specific expertise in ovarian cancer, endometrial cancer, endometriosis, metastasis mechanisms, ascites biology, and cell-free DNA analysis. Major projects include developing an early detection test for ovarian cancer and identifying key targets for anti-metastatic therapies. The GCRG works closely with clinicians at the Royal Hospital for Women and conducts studies involving biospecimen collection from women with gynaecological cancers. Professor Ford has pioneered innovative in vitro organotypic models of ovarian and endometrial cancer for pre-clinical drug testing. Her publication record shows consistent focus on ROR1/ROR2 receptors, Wnt signaling pathways, and cell-free DNA applications in cancer diagnostics. Recent work has emphasized liquid biopsy techniques using ascites fluid, 3D cancer models, and computational approaches to predict treatment outcomes. She has published extensively on the molecular mechanisms of gynaecological cancers and their clinical applications. Superstar of STEM (2017) Women's Agenda Award for Female Leader in Science, Medicine & Health (2018) Professor Ford actively supervises PhD students including Kate Gunther and Bonnie Werner, and co-supervises Zoe Phan. She convenes UNSW's General Education course on Personalised Medicine and developed Australia's first MOOC on this subject. She serves as Chair of the ANZGOG Uterine Tumour Type Working Group and Research Chair of Cure Cancer Australia. Her community engagement includes founding the STEMMinist Book Club and leading the 'Ovaries. Talk About Them' campaign to raise awareness about ovarian cancer.

• Cancer Cell Biology
• Gynaecological Cancer
• Ovarian Cancer
• +6 more

Professor Annette Byrne is a leading academic at RCSI University of Medicine and Health Sciences , where she serves as Professor of Physiology and Head of the Precision Cancer Medicine (PCM) Group. She has held this position since 2019 after progressing through roles as Lecturer (2008), Senior Lecturer (2013), and Associate Professor (2017). Her research focuses on precision medicine approaches for colorectal and brain cancers , integrating multi-modality molecular imaging , Next Generation Sequencing , and patient-derived xenograft models . PhD in Cell Biology (University of York, 1999) John Kerner Fellowship in Gynaecologic Oncology (UCSF, 1999-2001) Scientist at Pharmacyclics Inc. (2001-2003) Senior Scientist at Angion Biomedica Corp. (2003-2005) Principal Investigator at UCD Conway Institute (2005-2008) Her research interest lies in precision cancer medicine , particularly elucidating predictive biomarkers (genomic, transcriptomic, proteomic) and identifying novel therapeutic targets . Key methodologies include radiomics , fluorescence-guided surgery , and systems modeling of apoptosis pathways. She has pioneered Ireland's first Tumour Xenograft Facility and Translational In Vivo Imaging Centre . Recent publications highlight her work on cross-species radiomics , cell-free DNA analysis , and glioblastoma microenvironment subtyping . Her Marie Curie networks (Gliotrain, Glioresolve) and COLOSSUS project have trained 25+ PhD researchers in brain cancer therapeutics. Over €45M in national/international grants Member of Royal Irish Academy (2025) Highly cited in Cancer Discovery , Annals of Oncology , and Nature journals She supervises multiple PhD candidates and leads the RCSI Precision Cancer Medicine Group , which utilizes computational approaches and molecular imaging to improve cancer treatment outcomes. Her GLIORESOLVE and EDIReX projects focus on tumor microenvironment manipulation and distributed PDX infrastructure.

• Precision Medicine
• Molecular Imaging
• Angiogenesis
• +7 more

Dr. Yazan Abdallah is an Honorary Clinical Lecturer in the Department of Metabolism, Digestion and Reproduction at Imperial College London's Faculty of Medicine. He is a Consultant in Reproductive Medicine and Surgery at St Mary's Hospital, Manchester, with dual GMC accreditation in Obstetrics & Gynaecology and Reproductive Medicine. MD (2005), PhD (2014) H-index of 18 with over 30 peer-reviewed publications Specializes in fertility preservation for cancer survivors His research focuses on: Reproductive Medicine Ultrasound Imaging (3D, blood flow studies) Recurrent Miscarriage Diagnosis Uterine Transplantation Immune Suppression Cesarean Scar Analysis His work has led to international guideline changes (RCOG/NICE) and collaborations with KU Leuven. He has received the National Institute for Health Research (NIHR) Award and participated in the International Ovarian Tumor Analysis (IOTA) group. Recent publications analyze pregnancy outcomes, diagnostic ultrasound reproducibility, and fertility preservation in oncology.

• Reproductive Medicine
• Fertility Preservation
• Ultrasound Imaging
• +3 more

Clinical Professor Rodney Baber is affiliated with the University of Sydney through its Northern Clinical School in the Department of Obstetrics, Gynaecology and Neonatology . His research focuses on Reproductive medicine , Menopause , and Premature Ovarian Failure , with particular emphasis on hormone therapy applications and postmenopausal health risks. Obstetrics and Gynaecology Menopausal Medicine Reproductive Endocrinology Non-hormonal Therapies Recent publications demonstrate strong engagement with menopausal hormone therapy controversies, cardiovascular risk assessment , non-hormonal treatment alternatives , and postmenopausal complication management . Collaborative work with international experts appears across multiple high-impact journals.

• Reproductive medicine
• Menopause
• Premature Ovarian Failure

Patricia Roxburgh is a Professor of Experimental Cancer Medicine at the University of Glasgow, affiliated with the Clinical Research Garscube. Her research focuses on gynaecological cancers, particularly ovarian and colorectal malignancies, with an emphasis on genomic alterations, targeted therapies, and clinical trial design. Education: Not explicitly stated Appointments: University of Glasgow, Beatson Cancer Charity, Cancer Research UK Roxburgh's work spans BRCA mutations, PARP inhibitors, and the role of biomarkers like p53 and CA-125 in treatment response. She explores epigenetic mechanisms, immune modulation, and precision medicine strategies. The 15 most recent articles highlight her contributions to ovarian cancer genomics (e.g., structural variants, multiomic patient stratification), drug combination studies (PARP inhibitors with immunotherapies, capecitabine with radiotherapy), and biomarker validation (CA-125 as a prognostic indicator, p53 mutation dynamics). Grants: Genomic landscape of ovarian cancer (Tenovus Scotland), IMAGINE (Beatson Cancer Charity), PAIRS (Wellbeing of Women), Precision Medicine Laboratory sequencing (Beatson Cancer Charity) Current Projects: ECMC QQR, CRUK Centre Renewal, NHS ovarian cancer studies Roxburgh collaborates with teams at the Institute of Cancer Sciences and participates in clinical trials targeting chemoresistance, immunotherapy, and personalized treatment regimens.

• Experimental Cancer Medicine
• Ovarian Cancer
• Colorectal Cancer
• +3 more

Dr. Md Reduanul Hossain is a Research Fellow at the University of Newcastle's School of Medicine and Public Health, specializing in reproductive medicine within the Mothers and Babies Research Program. He holds a PhD in Reproductive Medicine (Newcastle) and dual Master's degrees (MSc Pharmaceutical Science, MPhil) from the University of Greenwich, UK. His research integrates reproductive biology, nanomedicine, and pharmacology, focusing on: Developing uterine-targeted nanoparticle systems for preterm birth prevention Identifying synergistic tocolytic drug combinations using human tissue models Investigating placental exosomes in uterine contractility Creating precision medicine approaches for gynaecological cancers via patient-derived xenografts/organoids Publications emphasize tocolytic efficacy , nanoparticle drug delivery , and myometrial physiology , with recent work advancing quantitative methods for contraction analysis and low-dose combination therapies. Awards & Grants: Animal Welfare Award (2023) UNRSC/UNIPRS Scholarships (2017) $78,726 in active funding for placental biopsy/exosome projects (2025–2026) He mentors students through Honours/Master's projects in reproductive sciences and molecular biology, though no named advisees are documented.

• Reproductive Medicine
• Cancer Cell Biology
• Nanomedicine
• +5 more

Associate Professor Katrin Sjoquist is a Senior Research Fellow and Clinical Lead at the NHMRC Clinical Trials Centre (CTC), part of the Faculty of Medicine and Health at the University of Sydney. She is also a practising medical oncologist specializing in gastrointestinal and rare cancers. Since joining the CTC in 2010, she has focused on clinical trials in oncology, earning a PhD in clinical trial design and evaluation. Her roles include coordinating the AGITG trials and leading the Cancer Australia-funded Genomics Cancer Clinical Trials Initiative (GCCTI) and the Molecular Screening and Therapeutics (MoST) programme. Research Interests: Design and management of Phase II/III clinical trials, evidence-based medicine, gastrointestinal and rare cancers, and evaluating treatment benefits versus harms. Her work spans oncology drug development, precision medicine, and translational research. Publications: Over 100 peer-reviewed articles, including high-impact studies in Journal of Clinical Oncology , Clinical Cancer Research , and British Journal of Cancer . Recent work focuses on regorafenib in gastric cancer, cell-free DNA biomarkers, and clinical trial methodologies. Grants and Leadership: Principal investigator on grants such as the Biliary Tract Registry Development (2023), and leadership roles in international trials like INTEGRATE II and NuTide:121. Collaborates with institutions like the Garvan Institute. Labs/Teams: CTC, AGITG, and MoST programme. Her work emphasizes collaborative, multi-institutional research to advance oncology treatments.

• Oncology
• Clinical Trials
• Gastrointestinal Cancers
• +3 more

Iva Filipovic serves as a Research Specialist in the Department of Laboratory Medicine, Division of Clinical Microbiology at Karolinska Institutet since 2025, following her Postdoctoral Research Fellowship (2019-2025) at the Department of Medicine Huddinge, Center for Infectious Medicine. She contributes to The Systems Virology Lab under Ujjwal Neogi, focusing on translational immunology in medical contexts. Her educational background includes: PhD in Physiology, Development and Neuroscience (Reproductive Immunology), University of Cambridge (2019) MSc in Immunology, Imperial College London (2015) BSc in Molecular Biology with Physiology, University of Belgrade (2014) Her research integrates tissue-resident immunology with systems approaches, examining innate lymphocytes in reproductive health, infectious diseases, and cancer. She employs advanced methodologies including RNA-Seq, single-cell analysis, and 29-color flow cytometry to investigate immune mechanisms in endometrial tissue, liver fibrosis, and viral pathogenesis. Current work emphasizes translational applications in sepsis, cholangiocarcinoma, and SARS-CoV-2 immunity. Analysis of her 15 most recent publications (2018-2025) reveals dominant themes in mucosal immunology, with significant contributions to understanding MAIT cells in sepsis, NK cell dynamics in reproduction, and immune biomarkers in cancer. Her work consistently bridges basic immunology with clinical applications through multi-omics approaches and large-scale collaborative studies like the Karolinska KI/K COVID-19 immune atlas. She actively participates in The Systems Virology Lab, contributing to Karolinska's infectious disease research infrastructure. Her technical expertise in high-dimensional immune profiling supports collaborative projects across virology, hepatology, and oncology research groups at Karolinska Institutet.

• Cancer and Oncology
• Gynaecology, Obstetrics and Reproductive Medicine
• Immunology in the Medical Area
• +2 more

Prof. Ate van der Zee is a Professor of Gynecologic Oncology and Chairman of the Board of Directors at University Medical Center Groningen (UMCG). He leads the Department of Gynecologic Oncology and is a global authority in vulvar and ovarian cancer research. His work focuses on clinical trials, translational research, and improving patient care through managed clinical networks. He holds leadership roles in multiple national/international organizations, including the Dutch Federation of University Medical Centers and the European Society of Gynaecological Oncology (past president). His research spans prognostic biomarkers, sentinel node procedures, and cancer treatment protocols. Prof. van der Zee has authored >270 peer-reviewed publications and supervised 40 PhD students. He combines administrative leadership with active clinical practice, surgical expertise, and mentoring.

• Gynecologic Oncology
• Oncology
• Vulvar Cancer
• +5 more

Professor Andreas Obermair is the Director of Queensland Centre for Gynaecological Cancer Research (QCGC Research) and a Professor of Gynaecological Oncology at The University of Queensland since 2007. He holds an Honorary Professor title at UQ since 2006 and serves as a Senior Medical Officer at Royal Brisbane & Women's Hospital, along with Visiting Medical Officer positions at St Andrews War Memorial Hospital and Buderim Private Hospital. As an NHMRC Leadership Fellow and Affiliate of the Centre for Extracellular Vesicle Nanomedicine, he leads significant research initiatives in gynaecological oncology. Professor Obermair's research spans multiple critical areas in gynaecological oncology including clinical trials methodology, where he emphasizes evidence-based approaches to cancer management; translational research applying new technologies to prevention and treatment; quality of life studies focusing on ovarian, endometrial, cervical and vulval cancers; and minimally invasive surgical techniques like total laparoscopic hysterectomy. His work has demonstrated that systematic training and mentoring can overcome barriers to adopting less-invasive surgical approaches that improve patient outcomes. His recent publications reveal a strong focus on improving cancer care through innovative approaches including telehealth follow-up for ovarian cancer patients, surgical complication management, vulval cancer treatment patterns, hormone therapy impacts, and immunotherapy applications for endometrial cancer. His research consistently addresses both clinical outcomes and patient quality of life considerations across various gynaecological cancers. NHMRC Investigator Fellowship Level 2 (2021-25) Cancer Australia's Jeannie Ferris Recognition Award (2017) for outstanding achievements in clinical practice and research Professor Obermair actively supervises multiple PhD and MPhil students working on biomarker research, patterns of care in endometrial cancer, and lifestyle factors affecting cancer outcomes. He has secured substantial funding from NHMRC, Cancer Australia, and the Cherish Women's Cancer Foundation for projects including the ALIVE WELL Centre of Research Excellence, the ANVU trial for vulvar cancer, and multiple clinical trials addressing precision surgery and treatment options for gynaecological cancers. He co-founded and serves on the Board of the Cherish Foundation, which funds clinical research for women with gynaecological cancers, demonstrating his commitment to consumer-focused research.

• Gynaecological Oncology
• Clinical Trials
• Translational Research
• +8 more

Valerie A Capstick is an Associate Professor in the Department of Obstetrics and Gynaecology at the University of Alberta's Faculty of Medicine & Dentistry, where she specializes in gynecologic oncology with emphasis on ovarian cancer management and women's health. Her educational background includes: Medical degree from University of Alberta (1983) Residency training at University of Alberta Fellowship in Gynecologic Oncology at University of Toronto Dr. Capstick's research focuses on hereditary ovarian cancer pathways, surgical and chemotherapeutic interventions for ovarian malignancies, and comprehensive management of uterine, cervical, and vulvar cancers. She actively investigates cervical precancerous lesion treatments and integrates clinical innovation with undergraduate medical education curriculum development. Her work bridges translational research and patient-centered care in gynecologic oncology. Her 2019 BMJ Open publication examining cost-awareness campaigns in laparoscopic hysterectomy demonstrates her expanding research scope into surgical resource optimization and healthcare economics within gynecologic procedures, reflecting contemporary trends in value-based surgical practice. As an educator, Dr. Capstick contributes significantly to undergraduate medical training at the University of Alberta, though specific graduate student mentorship details and research grant portfolios are not documented in available sources.

• Hereditary Ovarian Cancer
• Ovarian Cancer Surgery
• Ovarian Cancer Chemotherapy
• +7 more